Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society
复制标题
DOI：
10.1111/head.13625
复制
发表时间：
2019-09-01
期刊：
影响因子：
5
通讯作者：
Hershey, Andrew D.
中科院分区：
文献类型：
--
作者：
Oskoui, Maryam;Pringsheim, Tamara;Hershey, Andrew D.
目的为儿童偏头痛的预防提供最新的循证医学建议。方法作者系统回顾了2003年1月至2017年8月的文献，并使用美国神经病学学会2011年修订的过程制定了实践建议。结果15项关于青少年儿童偏头痛预防的I-III类研究符合纳入标准。没有足够的证据来确定接受双丙戊酸钠、奥那肉毒毒素A、阿米替林、尼莫地平和氟桂利嗪的儿童和青少年是否比接受安慰剂的儿童和青少年更有可能或更少可能减少头痛频率。患有偏头痛的儿童接受普萘洛尔治疗可能比接受安慰剂治疗的儿童头痛频率至少减少50%。接受托吡酯和桂利嗪的儿童和青少年可能比接受安慰剂的儿童和青少年更有可能减少头痛频率。偏头痛儿童接受阿米替林加认知行为治疗比接受阿米替林加头痛教育更可能减少头痛频率。大多数研究儿童偏头痛预防药物疗效的随机对照试验未能证明其优于安慰剂。预防儿童偏头痛的建议包括对影响头痛频率的生活方式和行为因素进行咨询，以及评估和管理与头痛持续相关的共病疾病。临床医生应与患者和护理人员共同决策偏头痛的预防性治疗，包括讨论支持药物治疗的证据的局限性。
Objective To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population. Methods The authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended. Results Fifteen class I-III studies on migraine prevention in children in adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine and flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have an at least 50% reduction in headache frequency. Children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have a decrease in headache frequency. Children with migraine receiving amitriptyline plus cognitive behavioral therapy are more likely than those receiving amitriptyline plus headache education to have a reduction in headache frequency. Recommendations The majority of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency, and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision making with patients and caregivers regarding the use of preventive treatments for migraine, including discussion of the limitations in the evidence to support pharmacologic treatments.